dc.contributor.author
López Muñoz, Laura
dc.contributor.author
Sanz, Ferran
dc.contributor.author
Pastor Maeso, Manuel
dc.contributor.author
Selent, Jana
dc.contributor.author
Loza, María I.
dc.contributor.author
Brea, José
dc.contributor.author
Areias, Filipe
dc.contributor.author
Ortega, Raquel
dc.contributor.author
Masaguer, Christian F.
dc.contributor.author
Raviña, Enrique
dc.date.issued
2011-07-27T08:27:54Z
dc.date.issued
2011-07-27T08:27:54Z
dc.identifier
Ortega R, Raviña E, Masaguer CF, Areias F, Brea J, Loza MI et al. Synthesis, binding affinity and SAR of new benzolactam derivatives as dopamine D3 receptor ligands. Bioorg Med Chem Lett. 2009;19(6):1773-8. DOI: 10.1016/j.bmcl.2009.01.067
dc.identifier
http://hdl.handle.net/10230/12424
dc.identifier
http://dx.doi.org/10.1016/j.bmcl.2009.01.067
dc.description.abstract
A series of new benzolactam derivatives was synthesized and the derivatives were evaluated for their/naffinities at the dopamine D1, D2, and D3 receptors. Some of these compounds showed high D2 and/or/nD3 affinity and selectivity over the D1 receptor. The SAR study of these compounds revealed structural/ncharacteristics that decisively influenced their D2 and D3 affinities. Structural models of the complexes/nbetween some of the most representative compounds of this series and the D2 and D3 receptors were/nobtained with the aim of rationalizing the observed experimental results. Moreover, selected compounds/nshowed moderate binding affinity on 5-HT2A which could contribute to reducing the occurrence of extrapyramidal/nside effects as potential antipsychotics.
dc.format
application/pdf
dc.format
application/pdf
dc.relation
Bioorganic and Medicinal Chemistry Letters. 2009;19(6):1773-8
dc.rights
© Elsevier (http://dx.doi.org/10.1016/j.bmcl.2009.01.067)
dc.rights
info:eu-repo/semantics/openAccess
dc.subject
Dopamina -- Receptors
dc.subject
Dopamine receptors
dc.subject
Arylpiperazines
dc.subject
Structure-activity relationship
dc.subject
Antipsychotics
dc.title
Synthesis, binding affinity and SAR of new benzolactam derivatives as dopamine D3 receptor ligands
dc.type
info:eu-repo/semantics/article
dc.type
info:eu-repo/semantics/publishedVersion